Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.810
+0.1301.34%
Volume:74.88M
Turnover:730.98M
Market Cap:113.03B
PE:23.71
High:9.830
Open:9.600
Low:9.600
Close:9.680
52wk High:11.454
52wk Low:4.210
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.96
T/O Rate:0.65%
Dividend:0.24
Dividend Rate:2.44%
EPS(LYR):0.414
ROE:10.83%
ROA:5.65%
PB:3.03
PE(LYR):23.71
PS:3.84

Loading ...

Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Dual Hypertension And Diabetes Pipeline Updates

Simply Wall St.
·
4 hours ago

CSPC PHARMA (01093) Grants a Total of 46.4625 Million Award Shares

Stock News
·
Yesterday

CSPC Pharmaceutical Group Stock Rallies 1.3% in Hong Kong

Dow Jones
·
Yesterday

CSPC Pharmaceutical Group Stock Rallies 1.6% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 21

CSPC Pharmaceutical - Sees FY Net Loss Attributable Between RMB170 Mln & RMB255 Mln for CSPC Innovation Pharmaceutical

THOMSON REUTERS
·
Jan 15

CSPC Innovation Pharmaceutical Reports Full-Year Net Loss for 2025

Reuters
·
Jan 15

After Leaping 28% CSPC Pharmaceutical Group Limited (HKG:1093) Shares Are Not Flying Under The Radar

Simply Wall St.
·
Jan 14

CSPC PHARMA (01093): Potent Aldosterone Synthase Inhibitor (SYH2072 Tablets) Receives Clinical Trial Approval in the US

Stock News
·
Jan 13

CSPC Pharmaceutical - Syh2072 Tablets Approved for Clinical Trials by China Nmpa

THOMSON REUTERS
·
Jan 13

CSPC Pharmaceutical - Potent Aldosterone Synthase Inhibitor (Syh2072 Tablets) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Jan 13

CSPC Pharmaceutical Group Wins US FDA Approval for SYH2072 Clinical Trials

Reuters
·
Jan 13

CSPC Pharma's Marketing Application for Glycemic Control Drug Accepted in China

MT Newswires Live
·
Jan 12

CSPC PHARMA (01093): Marketing Application for Puluoglitin Metformin Sustained-Release Tablets Accepted by NMPA

Stock News
·
Jan 12

NMPA Accepts Marketing Authorisation Application for CSPC Prusogliptin and Metformin Extended-Release Tablets

Reuters
·
Jan 12

CSPC Pharmaceutical Group Stock Advances 3.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 12

CSPC Pharmaceutical Group (SEHK:1093) Is Up 8.2% After Multiple Novel Metabolic And Respiratory Trial Approvals – What's Changed

Simply Wall St.
·
Jan 08

CSPC Pharmaceutical Group Stock Rallies 2.9% in Hong Kong

Dow Jones
·
Jan 07

CSPC PHARMA (01093) Rises Over 3% as Empagliflozin Tablet Application Gets Accepted

Stock News
·
Jan 07

CSPC Pharmaceutical Group Stock Advances 4.8% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 05

BREAKINGVIEWS-Biotech boom shows innovation is now made in China

Reuters
·
Jan 05